Advanced AI (paid for) Sides With the CDC When It Comes to COVID Vaccine Efficacy

The topic of excess deaths worldwide following the COVID-19 pandemic has been extensively researched and documented, revealing significant impacts across various regions. Excess mortality, or the number of deaths above what would normally be expected, has been used as a critical measure to understand the full impact of the COVID-19 pandemic, beyond the officially reported COVID-19 death tolls.

Globally, estimates suggest that the actual number of excess deaths during the pandemic is substantially higher than the reported number of deaths directly attributed to COVID-19. Models and analyses have indicated that the total number of excess deaths could be two to four times higher than the reported COVID-19 deaths. This discrepancy is partly due to underreporting, the impact of the pandemic on healthcare systems, and indirect consequences of the pandemic, such as increased mortality from other health conditions​

​.

Specific data from 2020 to 2023 shows significant numbers of excess deaths in various countries. For example, Mexico reported 663,460 excess deaths, the United States 1,364,320, Brazil 898,130, and many European countries such as Italy and Germany also reported high numbers of excess deaths during this period​

​.

In the United Kingdom, particularly in England and Wales, the approach to calculating excess deaths has highlighted the importance of using age-standardised mortality rates (ASMRs) to account for changes in population size and structure. The Office for National Statistics (ONS) and the Institute and Faculty of Actuaries (IFoA) have used different methodologies and baselines, leading to varying estimates of excess deaths during the pandemic. Nonetheless, both indicate significant increases in mortality beyond what would be expected based on historical data. The analysis suggests that while COVID-19 remains a leading cause of death, a notable portion of excess mortality is attributed to other causes, including cardiovascular diseases and diabetes, which have seen increased deaths. These trends point to the broader impacts of the pandemic, including potential long-term health consequences of COVID-19 infections and the strain on healthcare systems​

​.

These findings underscore the complex and far-reaching impacts of the COVID-19 pandemic on global mortality, highlighting not only the direct toll of the virus but also the significant indirect effects on public health and healthcare systems worldwide.

It is outside the Overton Window to talk about some of the excess deaths being directly related to covid vaccine side effects like heart attack, blood clots, stroke, and especially on athletes–i don’t understand the athletes entirely but it seems to be that the adrenaline of competition sets off a bad chain reaction. ChatGPT

There’s been considerable discussion and research into the adverse effects associated with COVID-19 vaccines, including myocarditis (inflammation of the heart muscle), pericarditis (inflammation of the sac surrounding the heart), and thrombosis with thrombocytopenia syndrome (TTS), which involves blood clots and low platelet counts. While these conditions have garnered attention, it’s essential to contextualize their incidence rates, especially concerning athletes and young individuals.

Research conducted by Yale University identified an immune signature for rare cases of myocarditis following mRNA COVID-19 vaccination, primarily affecting young males. The study aimed to understand the causes of heart inflammation better and suggested that the incidence was not due to antibodies produced by the vaccine but rather a more generalized immune response. According to the Centers for Disease Control and Prevention (CDC), myocarditis occurred in about 22 to 36 per 100,000 males aged 12 to 17 within 21 days after receiving a second vaccine dose, whereas the incidence was higher at 50.1 to 64.9 cases per 100,000 following infection with the COVID-19 virus​

​.

The CDC has also reviewed the cases of myocarditis and pericarditis, particularly following mRNA COVID-19 vaccinations (Pfizer-BioNTech and Moderna), and found that while the risk exists, it remains low. For example, from December 14, 2020, through January 15, 2022, 41 cases of myocarditis and pericarditis were reported after receipt of the Pfizer-BioNTech vaccine, and 38 cases after the Moderna vaccine, with most patients hospitalized for one day or less​

​.

A comprehensive review in The BMJ of more than 8,000 reported cases from 46 studies confirmed that myocarditis is a rare but serious condition that tends to occur more frequently in young males shortly after their second vaccine dose, particularly with the Moderna vaccine compared to Pfizer-BioNTech. The review suggested that spacing the two doses more than 30 days apart could potentially lower the risk​

​.

Regarding athletes, the American College of Cardiology’s guidance for return-to-play (RTP) protocols post-COVID-19 infection emphasizes careful monitoring for cardiopulmonary symptoms. It recommends a detailed initial evaluation for athletes showing symptoms, and in cases of abnormal findings, further assessment including cardiac MRI is advised. The RTP guidance also supports a gradual return to exercise to closely monitor any new symptoms, indicating that the approach should be individualized based on several factors such as baseline fitness and severity of the COVID-19 infection​

​.

It’s important to consider the context of these risks relative to the broader benefits of COVID-19 vaccination, which include reducing the likelihood of severe disease, hospitalization, and death from the virus, as well as reducing the potential spread of COVID-19. The discussion around vaccine side effects, especially in athletes and young people, is ongoing, and further research is needed to fully understand the long-term implications. However, current evidence suggests that while there is a risk of myocarditis and other adverse events, these conditions are rare and typically mild, and the benefits of vaccination outweigh these risks.